ACR Image Metrix, a global imaging contract research organisation (CRO) based in the American College of Radiology Clinical Research Center in Philadelphia, US, has welcomed Kathy Freeman as business development manager for the East Coast of the US.
Freeman has extensive experience in sales strategies, team leadership and new market development.
Prior to joining ACR Image Metrix, Freeman held key positions within niche CRO organisations, where she landed numerous contracts in the pharmaceutical and biotech market. She began her career selling specialist pharmaceuticals.
ACR Image Metrix provides imaging CRO services to assist pharmaceutical, biotech and medical device companies around the world.
ACR Image Metrix hires Kathy Freeman
As business development manager for the US East Coast
You may also like
Regulatory
![Early phase analytical strategy for biosimilars in a shifting regulatory landscape]()
Early phase analytical strategy for biosimilars in a shifting regulatory landscape
As FDA and EMA guidance continues to reinforce analytical comparability as the foundation of biosimilar development, investing in comprehensive early-stage characterisation is becoming essential to reduce uncertainty and improve development outcomes, says Dr Andrew J. Reason, CEO at BioPharmaSpec
Design & Build
![Theolytics expands Oxford biotech operations with new facility to advance THEO-260 cancer immunotherapy]()
Theolytics expands Oxford biotech operations with new facility to advance THEO-260 cancer immunotherapy
The clinical-stage biotech has relocated to ARC Oxford, strengthening its R&D capabilities as it progresses clinical trials of its oncolytic immunotherapy candidate THEO-260 for ovarian cancer and other solid tumours
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
![Precision medicine and the fight to revive neuroscience R&D]()
Precision medicine and the fight to revive neuroscience R&D
In discussion with Dr Kevin Robinson (KSR), Neurvati’s Dr Bruce Leuchter (BL) explores how biology-led development, better diagnosis and rare disease infrastructure could help to unlock stalled neuroscience programmes
Research & Development
![Grünenthal joins genetic medicine cluster CNATM to advance RNA therapeutics]()
Grünenthal joins genetic medicine cluster CNATM to advance RNA therapeutics
The pain specialist has joined the Cluster for Nucleic Acid Therapeutics Munich to strengthen its oligonucleotide drug discovery capabilities and accelerate the development of genetic medicines for neurological diseases